Clinical trial · Observational
Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
Epidemiological Study of the Therapeutic Management of Well-differentiated Grade 3 (WHO Classification) Neuroendocrine Digestive Tumors From the Prospective Data of the French Neuroendocrine Tumors Registry (GTE)
NCT04365023CI-TRIAL-00103257TNE-bien-DIFcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to analyse clinical data of well-differentiated grade 3 digestive neuroendocrine tumors. These rare tumors may have a different disease evolution, response to chemotherapy and prognostic.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| platinum chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
- interventionNames
- Drug: platinum chemotherapy
- label
- 2
- description
- Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
Primary outcomes (1)
- measure
- Title : Overall survival
- timeFrame
- 12 months
- description
- To compare the median of overall survival of Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy versus patients receiving first line non-platinum chemotherapy
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Well-differentiated grade 3 neuroendocrine digestive tumors * Patient of 18 years old and more Exclusion Criteria: * Patient opposed to data collection as part of the study * Digestive neuroendocrine tumors Grade 1-2 * Grade 3 poorly differentiated digestive neuroendocrine tumors * Malignant disease diagnosed in the last 5 years (except basal cell of the skin and in situ cervical carcinoma) * Other non-digestive neuroendocrine tumors * Mixed neuroendocrine non neuroendocrine neoplasm
References
Publications (0)
Data not yet available
No reference posted for this study.